Subscription management platform RevenueCat raises $50 million in Series C funding
(Reuters) -Subscription management platform RevenueCat on Thursday raised $50 million in Series C funding, led by Bain Capital Ventures, along with participation from returning investors Index Ventures, Y Combinator, and Volo Ventures among others.
The rise of tools and software that make it easier to create apps has boosted demand for in-app monetization platforms like RevenueCat, which simplify managing pricing and subscriptions.
The San Francisco, California-based company counts OpenAI as a customer and worked with the AI firm to deploy ChatGPT on mobile following its remarkable debut in 2022.
CEO Jacob Eiting told Reuters that 20% of RevenueCat's top 20 apps are AI-based, as these apps can charge higher fees and achieve better conversion rates.
The surge in generative artificial intelligence has led to numerous AI startups requiring platforms to manage their subscription tiers as users increasingly turn to conversational chatbots for daily tasks.
With the new funding, RevenueCat plans to expand its workforce and pursue acquisitions.
The company is also making a significant push into the mobile gaming market, developing a virtual currency feature aimed at players who readily spend on in-game currency.
"We eventually hope to be as important in the game market as we are in the app market," Eiting said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Infosys (INFY) Delivers $19,277 million in Revenues in FY 2025
Infosys Limited (NYSE:INFY) is one of the Best Indian Stocks to Buy for Next 5 Years. In FY 2025, the company delivered $19,277 million in revenues, reflecting a rise of 4.2% in constant currency. Infosys Limited (NYSE:INFY)'s performance for the year remained robust in terms of revenues, expansion in operating margins, and the highest-ever free cash generation. Moving forward, the company's depth in AI, cloud, and digital, and its strength in cost efficiency, automation, and consolidation place it well. A programmer typing on a laptop, highlighting the cutting edge software engineering solutions provided by the company. Infosys Limited (NYSE:INFY) announced the expansion of its collaboration with Siemens AG in a bid to accelerate Siemens AG digital learning initiatives with Gen AI. For FY 2025, Infosys Limited (NYSE:INFY)'s FCF was the highest ever at $4.1 billion, reflecting an increase of 42% YoY. Notably, the FCF as a percentage of net profit for the financial year stood at 129%. The company expects FY 2026 FCF to be more than 100% of net profit. Infosys Limited (NYSE:INFY) highlighted that, because of recent tariff announcements, client budgets are expected to be tightened, while there remains an increased caution. Decision cycles have been getting stretched with respect to discretionary spend and large deals. Throughout the geos, there remains an increased focus on AI, cloud, estate modernization, cost takeout, and investments in core tech capabilities. Headquartered in Bengaluru, India, Infosys Limited (NYSE:INFY) provides consulting, technology, outsourcing, and digital services. While we acknowledge the potential of INFY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18 minutes ago
- Yahoo
Rezolve AI PLC (RZLV) To Support Stablecoin Transactions
Rezolve AI (NASDAQ:RZLV) is one of the top AI stocks with tremendous upside potential. On July 21, the company confirmed that its platform is well-positioned to support stablecoin transactions following the passing of the GENIUS Act. The passing of the GENIUS Act is welcome, as Rezolve AI has carved a niche in offering artificial intelligence-powered solutions that enhance customer engagement while optimizing revenue. Its platform delivers tools that utilize AI to improve the digital experience and decision-making processes. 'The GENIUS Act is expected to transform stablecoins from speculative assets into regulated digital dollars,' said Daniel M. Wagner, CEO of Rezolve AI. 'Tether's commitment to compliance is a milestone, and Rezolve believes it is ready to connect this new liquidity to the real economy.' The Rezolve AI Brain Suite platform is already integrated into Microsoft Azure and Google Cloud infrastructure to support wallet-based payments. The Microsoft and Google integrations enable enterprise-grade scalability and deployment, therefore exposing the company to a $30 trillion market globally. Rezolve AI (NASDAQ:RZLV) is a pure-play artificial intelligence (AI) company that develops proprietary Large Language Models (LLMs) tailored for the retail sector. Its Brain Suite of AI solutions helps retailers deepen customer engagement, streamline operations, and boost sales with scalable AI-driven tools. While we acknowledge the potential of RZLV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best Chemical Stocks to Buy According to Billionaires and 7 Most Undervalued Pot Stocks To Buy According To Analysts. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
18 minutes ago
- Yahoo
Vektor Medical's vMap Surpasses 2,000 Procedures, Driving a New Standard in Arrhythmia Care
Milestone Highlights Rapid Hospital Adoption and Clinical Demand for Arrhythmia Insights that Improve Outcomes and Reduce Procedure Time SAN DIEGO, July 23, 2025--(BUSINESS WIRE)--Vektor Medical today announced its vMap® system has been used in more than 2,000 procedures in the U.S., a milestone that underscores its rapid adoption by electrophysiologists (EPs) and hospitals seeking to improve procedural efficiency, reduce repeat interventions, and deliver better patient outcomes. vMap, developed with AI and designed to localize both focal and fibrillation-type arrhythmias, delivers actionable insights in all four chambers of the heart in less than a minute. Clinical studies have shown that use of vMap is associated with a reduction in procedure time, which may reduce fluoroscopy time and improve safety. vMap integrates seamlessly into existing systems, making it an increasingly valuable solution for electrophysiologists seeking greater efficiency and performance without compromise. vMap is now in use at over 20 hospitals throughout the United States. "vMap has become an integral part of how I care for patients," said Dr. Anish Amin, Section Chief, Electrophysiology, OhioHealth Heart and Vascular. "It's efficient, non-invasive, and delivers insights that enhance every stage of the ablation process from planning through execution. With vMap, I can pinpoint arrhythmia sources faster with greater confidence, treat more accurately, and potentially reduce repeat interventions for patients. I'm looking forward to enrolling patients in the IMPRoVED-AF study, which will further validate the clinical impact of this technology and its potential to transform how we approach AF ablation." As adoption of pulsed field ablation (PFA) accelerates, the need for accurate, accessible data is greater than ever. vMap can enhance the impact of PFA by helping EPs identify optimal ablation targets before entering the lab and reiteratively during the procedure. With vMap's rapid, non-invasive ECG-based driver localization, physicians have more information to better target areas of interest, supporting more efficient procedures and unlocking the full potential of PFA. "This milestone represents meaningful momentum," said Robert Krummen, CEO of Vektor Medical. "With every procedure, physicians are leveraging vMap's rapid, non-invasive insights to make informed decisions and streamline care. We're seeing growing demand quarter over quarter as both physicians and hospitals look for ways to enhance efficiency and elevate patient care." The vMap system is FDA-cleared and commercially available in the United States. As clinical use continues to expand, Vektor Medical remains focused on advancing the future of arrhythmia care through clinical innovation, strategic partnerships, and physician impact. To learn more about Vektor Medical, vMap technology, or to request a clinical or strategic briefing, visit and connect with us on LinkedIn and X. About Vektor Medical Headquartered in San Diego, Vektor Medical is redefining how arrhythmias are understood and treated. The company developed vMap®, the only FDA-cleared, non-invasive technology that uses standard 12-lead ECG data to localize arrhythmia source locations across all four chambers of the heart. By helping physicians identify arrhythmia drivers more quickly and with greater accuracy, Vektor is improving outcomes, enhancing efficiencies, and accelerating access to effective treatment strategies. To learn more, visit View source version on Contacts Media Contact Stacey HolifieldLevitate(617) 233-3873vektor@
